Information
-
Trademark
-
79409929
-
International Classifications
-
Filing Date
June 18, 2024
a year ago
-
Transaction Date
July 23, 2025
7 months ago
-
Status Date
July 22, 2025
7 months ago
-
Location Date
July 23, 2025
7 months ago
-
Status Code
661
-
Current Location
TMO LAW OFFICE 119
Employee Name
CORWIN, CHARLOTTE
-
Attorney Docket Number
22002.9
Attorney Name
David P. Johnson
Law Office Assigned Location Code
N10
-
Owners
Mark Drawing Code
4
Mark Identification
EXOEDIT
Case File Statements
- GS0051: Pharmaceuticals for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein or nucleic acids or viral vectors for therapy; medicine for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; medical preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for medical purposes for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; biological preparations comprising exosome for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations comprising a therapeutic target protein-loaded, nucleic acid-loaded or virus-loaded exosome for the treatment of genetic diseases, respiratory diseases, or cancer; biological reagents for medical use; mixed biological preparations for medical purposes for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; mixed biological preparations for the prevention and treatment of infectious diseases; extracellular vesicle-based nucleic acid preparations for therapeutical use for the prevention and treatment of infections or disease for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; gene therapy products, namely, gene delivery pharmaceuticals; pharmaceutical preparations for gene therapy, gene editing, and genome editing; pharmaceutical preparations for use in gene therapies for the treatment of genetic diseases and disorders
- PM0001: EXO EDIT
- GS0441: Medical services; medical and pharmaceutical consultancy; medical diagnostics; medical analysis for the diagnosis and treatment of persons and medical examinations; medical treatment services; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; information, advisory and consultancy services relating to the aforesaid
- GS0421: Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; research and analysis services in the field of pharmaceuticals; biological research; clinical research in the field of transformational therapeutics; providing medical research and scientific research information in the field of filtration of exosomes from cultured cells or blood; scientific investigations for medical purposes; scientific laboratory services; medical laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; medical laboratory diagnostics research services; genetic engineering services; genetic research; research in the field of gene editing technology; research in the field of DNA mutation; information, advisory and consultancy services relating to the aforesaid
Case File Event Statements
-
11/21/2024 - a year ago
1 - SN ASSIGNED FOR SECT 66A APPL FROM IB
Type: REPR
-
11/22/2024 - a year ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS
-
12/23/2024 - a year ago
5 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
12/24/2024 - a year ago
6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Type: RFCR
-
1/22/2025 - a year ago
8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Type: RFCS
-
1/22/2025 - a year ago
7 - REFUSAL PROCESSED BY MPU
Type: RFRR
-
2/9/2025 - a year ago
9 - REFUSAL PROCESSED BY IB
Type: RFNT
-
11/22/2024 - a year ago
3 - APPLICATION FILING RECEIPT MAILED
Type: MAFR
-
12/19/2024 - a year ago
4 - ASSIGNED TO EXAMINER
Type: DOCK
-
7/22/2025 - 7 months ago
11 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
7/22/2025 - 7 months ago
10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
7/22/2025 - 7 months ago
12 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME